Trial Profile
Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors Takeda
- 28 Jan 2023 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 16 Dec 2021 This trial has been completed in France as per European Clinical Trials Database record.
- 18 May 2017 This trial has been discontinued in Sweden.